Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
November 10, 2021 07:55 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
October 07, 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
September 29, 2021 09:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
September 13, 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431PK-PD models successfully predict early reductions in Pro-C3 and ALTHepion’s proprietary AI-POWR™ and machine...
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH
September 10, 2021 16:05 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
July 23, 2021 16:40 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
July 13, 2021 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Safety, Tolerability and Pharmacokinetics (“PK”) Primary Endpoints MetReductions in Liver Transaminases Indicate Dose-Related Improvements in Key NASH BiomarkerConcentration-Effect Relationship...
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
June 25, 2021 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
June 09, 2021 07:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
May 06, 2021 07:45 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...